DOR BioPharma, Inc. (DORB) Announces National Institutes of Health (NIH) Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis  
9/8/2009 8:42:34 AM

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis. The award will provide DOR with approximately $500,000 over a two-year period.